Risk factor
Very poor trading liquidity
Profitability factor
Weak growth
About
Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic drug offerings and innovative therapeutic solutions. The company's product line addresses a range of health challenges, including oncological conditions, neurological disorders, diabetes, and other metabolic complaints. Established in 2002, this enterprise is situated in Lomianki, Poland, and functions as a subsidiary of Glatton Sp. z o.o.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is underpriced on P/E, 'expensive' on EV/EBITD
Target Price
The average target price of CLN.WA is 20 and suggests 0.955% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to